Junctional Adhesion Molecule-Like Protein (JAML) Is Correlated with Prognosis and Immune Infiltrates in Lung Adenocarcinoma

16 January 2022: Database Analysis

Likui Fang ^ABCDEF , Wenfeng Yu ^BCD , Guocan Yu ^CDF , Fangming Zhong ^DF , Bo Ye ^ABCDEF*

DOI: 10.12659/MSM.933503

Med Sci Monit 2022; 28:e933503

Table 2 Cox regression analysis of JAML and clinicopathologic characteristics with survival outcomes in LUAD.

Characteristics	Univariate analysis			Multivariate analysis
Characteristics	HR	95% CI	P	HR	95% CI	P
Overall survival
Age (>65 vs ≤65)	1.223	0.916–1.635	0.172
Gender (Male vs Female)	1.070	0.803–1.426	0.642
Smoking history (Yes vs No)	0.894	0.592–1.348	0.591
T stage (T2 & T3 & T4 vs T1)	1.728	1.229–2.431	0.002	1.642	1.050–2.568	0.030
N stage (N1 & N2 & N3 vs N0)	2.601	1.944–3.480		1.837	1.029–3.280	0.040
M stage (M1 vs M0)	2.136	1.248–3.653	0.006	1.413	0.765–2.610	0.270
Pathologic stage (Stage II & Stage III & Stage IV vs Stage I)	2.933	2.173–3.958		1.435	0.769–2.677	0.257
JAML (High vs Low)	0.618	0.460–0.831	0.001	0.706	0.500–0.997	0.048
Progress free survival
Age (>65 vs ≤65)	1.023	0.784–1.335	0.867
Gender (Male vs Female)	1.172	0.901–1.526	0.236
Smoking history (Yes vs No)	0.968	0.658–1.426	0.870
T stage (T2 & T3 & T4 vs T1)	1.882	1.379–2.570		1.509	1.090–2.090	0.013
N stage (N1 & N2 & N3 vs N0)	1.512	1.152–1.984	0.003	0.851	0.562–1.288	0.445
M stage (M1 vs M0)	1.513	0.855–2.676	0.155
Pathologic stage (Stage II & Stage III & Stage IV vs Stage I)	1.960	1.502–2.557		1.851	1.221–2.806	0.004
JAML (High vs Low)	0.758	0.581–0.989	0.041	0.846	0.644–1.111	0.229